Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcos de Lima

Showing results (171-180 of 321) with videos related to

Pageof 33
Sort By:
Environmental Science and Pollution Research International|August 4, 2021
Treatment of cosmetic industry wastewater by flotation with Moringa oleifera Lam. and aluminum sulfate and toxicity assessment of the treated wastewaterNathalia Santos Araújo, Nathália Ferreira Souza, João Marcos de Lima-Faria, et al.
American Journal of Hematology|February 24, 2025
Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic LeukemiaMarcos de Lima, Partow Kebriaei, Francesco Lanza, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantationNaveen Pemmaraju, Maria Florencia Tanaka, Farhad Ravandi, et al.
Bone Marrow Transplantation|October 22, 2020
Correction: History of drug use in allogeneic hematopoietic cell transplant recipientsMouhamed Yazan Abou-Ismail, Gayathri Ravi, Pingfu Fu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Transplantation and Cellular Therapy|June 24, 2026
Outcomes of Tocilizumab for Cytokine Release Syndrome After Post-Transplant CyclophosphamideTuan L Phan, Roberta Azbell, Hannah Choe, et al.
Bone Marrow Transplantation|September 18, 2020
History of drug use in allogeneic hematopoietic cell transplant recipientsMouhamed Yazan Abou-Ismail, Gayathri Ravi, Pingfu Fu, et al.
Leukemia & Lymphoma|January 19, 2021
Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemiaJiasheng Wang, Marcos de Lima, Brenda W Cooper, et al.
Future Oncology (London, England)|December 8, 2025
Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summaryMarcos de Lima, Partow Kebriaei, Francesco Lanza, et al.
Blood|December 2, 2006
Hyperacute GVHD: risk factors, outcomes, and clinical implicationsRima M Saliba, Marcos de Lima, Sergio Giralt, et al.
Pageof 33

Showing results (171-180 of 321) with videos related to

Sort By:
Pageof 33
Environmental Science and Pollution Research International|August 4, 2021
Treatment of cosmetic industry wastewater by flotation with Moringa oleifera Lam. and aluminum sulfate and toxicity assessment of the treated wastewaterNathalia Santos Araújo, Nathália Ferreira Souza, João Marcos de Lima-Faria, et al.
American Journal of Hematology|February 24, 2025
Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic LeukemiaMarcos de Lima, Partow Kebriaei, Francesco Lanza, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantationNaveen Pemmaraju, Maria Florencia Tanaka, Farhad Ravandi, et al.
Bone Marrow Transplantation|October 22, 2020
Correction: History of drug use in allogeneic hematopoietic cell transplant recipientsMouhamed Yazan Abou-Ismail, Gayathri Ravi, Pingfu Fu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Transplantation and Cellular Therapy|June 24, 2026
Outcomes of Tocilizumab for Cytokine Release Syndrome After Post-Transplant CyclophosphamideTuan L Phan, Roberta Azbell, Hannah Choe, et al.
Bone Marrow Transplantation|September 18, 2020
History of drug use in allogeneic hematopoietic cell transplant recipientsMouhamed Yazan Abou-Ismail, Gayathri Ravi, Pingfu Fu, et al.
Leukemia & Lymphoma|January 19, 2021
Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemiaJiasheng Wang, Marcos de Lima, Brenda W Cooper, et al.
Future Oncology (London, England)|December 8, 2025
Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summaryMarcos de Lima, Partow Kebriaei, Francesco Lanza, et al.
Blood|December 2, 2006
Hyperacute GVHD: risk factors, outcomes, and clinical implicationsRima M Saliba, Marcos de Lima, Sergio Giralt, et al.
Pageof 33